FeesSafety
Pluang+

Law firm probes Omeros over stock drops after EMA rejects drug approval twice

Market News
20 Oct 2026, 23:02 WIB
GlobeNewsWire
View Source
Bearish
Law firm probes Omeros over stock drops after EMA rejects drug approval twice

Pomerantz LLP is investigating Omeros Corporation for potential securities fraud following two significant stock price drops after the European Medicines Agency (EMA) twice rejected Omeros's drug narsoplimab for treating TA-TMA. The first rejection in June 2026 caused a nearly 20% stock fall, and a second negative opinion in October 2026 led to another nearly 14% drop. The investigation focuses on whether Omeros and its executives engaged in unlawful practices related to these announcements. Investors affected by these events are encouraged to contact the law firm for potential class action participation.

Omeros Corporation news is the subject, with Pluang market data providing context. For readers following health-sector stocks, 124 of 150 US stocks rose and 26 fell on October 21, 2026, at 03:11 WIB. Notable movers include LQDA at USD 36.53 (+7.03%, 81% Sell / 19% Buy), MRNA at USD 242.45 (+6.86%, 40% Sell / 60% Buy), and DFTX at USD 35.19 (+6.73%).

More News

GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian expands program to alert companies of leaked credentials, boosting enterprise cybersecurity worldwide.

GitGuardian has launched the Enterprise Good Samaritan Program to identify and notify companies about high-impact leaked credentials that could expose their systems to attackers. Using AI and expert analysis, the program traces leaks to affected orga...

Market News
Neutral
1 hour ago
Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo renews share buyback plan to repurchase up to 10% of public shares by Nov 2027

Saputo Inc. has renewed its Normal Course Issuer Bid (NCIB), allowing it to repurchase up to 22.5 million common shares, representing 10% of its public float, from November 19, 2026, to November 18, 2027. This move reflects Saputo's strategy to retur...

Company Fundamentals
Bullish
1 hour ago
Saputo renews share buyback program to repurchase up to 10% of public shares through Nov 2027.

Saputo renews share buyback program to repurchase up to 10% of public shares through Nov 2027.

Saputo Inc. announced the renewal of its normal course issuer bid, allowing it to repurchase up to 22.5 million ordinary shares, representing 10% of its public float, from November 19, 2026, to November 18, 2027. This move reflects Saputo's ongoing c...

Company Fundamentals
Bullish
1 hour ago
Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo plc and Curio Legacy Ventures announced a collaboration to supply recycled nuclear materials for mixed-oxide (MOX) fuel production at Newcleo's planned US fuel manufacturing facility. This partnership combines Curio's NuCycle recycling techno...

Market News
Bullish
2 hours ago
Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics announced a 38% year-over-year revenue increase for Q3 2026, driven by its IC Drone insulator-cleaning activities. The company expanded its IC Drone platform into Greece through a strategic collaboration with CRONOS, identifying potenti...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App